Clemens B Tempfer1, Günther A Rezniczek2, Paula Ende2, Wiebke Solass3, Marc-André Reymond4. 1. Department of Obstetrics and Gynecology, Ruhr University Bochum, Bochum, Germany clemens.tempfer@rub.de. 2. Department of Obstetrics and Gynecology, Ruhr University Bochum, Bochum, Germany. 3. Institute of Pathology, Medical School Hannover, Hannover, Germany. 4. Department of Surgery, Ruhr University Bochum, Bochum, Germany.
Abstract
AIM: We aimed to assess the objective tumor response (OTR) to laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with peritoneal carcinomatosis (PC). PATIENTS AND METHODS: We carried-out a retrospective cohort study of women with PC undergoing repeated courses of PIPAC with 7.5 mg/m(2) of cisplatin and 1.5 mg/m(2) of doxorubicin. OTR was defined as histological regression. Peritoneal carcinomatosis index (PCI) improvement on video-laparoscopy and ascites volume reduction were secondary outcomes. Quality of life was assessed by the European Organization for Research & Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-30+3. RESULTS: A total of 252 PIPACs were performed in 99 women with PC and ovarian (n=84), primary peritoneal (n=6), cervical (n=3), endometrial (n=3), fallopian tube (n=1), and breast (n=1) cancer and pseudomyxoma peritonei (n=1). Laparoscopic non-access rate was 17% (17/99). Fifty women had more than one PIPAC procedures, with an OTR of 76% (38/50) and PCI improvement in 64% (32/50). Ascites volume significantly decreased from 762±1170 ml to 167±456 ml (p=0.02). A high initial Karnofsky Index was correlated with receiving more than one PIPAC (p<0.0001) and a high number of previous surgeries with laparoscopic non-access (p=0.01). Twenty adverse events of Common Terminology Criteria for Adverse Events grade 3 or more were noted. Absence of ascites (odds ratio=8.45, 95% confidence interval=1.9-3.6; p<0.0001), but not patient age, serum cancer antigen-125, and Karnofsky Index independently predicted OTR. EORTC QLQ-30+3 scores for global physical health, nausea/vomiting, appetite loss, and constipation improved during therapy. CONCLUSION: PIPAC with cisplatin and doxorubicin is an active treatment in women with PC and preserves quality of life. Appropriate patient selection regarding performance status and the number of prior surgeries is important. Copyright
AIM: We aimed to assess the objective tumor response (OTR) to laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with peritoneal carcinomatosis (PC). PATIENTS AND METHODS: We carried-out a retrospective cohort study of women with PC undergoing repeated courses of PIPAC with 7.5 mg/m(2) of cisplatin and 1.5 mg/m(2) of doxorubicin. OTR was defined as histological regression. Peritoneal carcinomatosis index (PCI) improvement on video-laparoscopy and ascites volume reduction were secondary outcomes. Quality of life was assessed by the European Organization for Research & Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-30+3. RESULTS: A total of 252 PIPACs were performed in 99 women with PC and ovarian (n=84), primary peritoneal (n=6), cervical (n=3), endometrial (n=3), fallopian tube (n=1), and breast (n=1) cancer and pseudomyxoma peritonei (n=1). Laparoscopic non-access rate was 17% (17/99). Fifty women had more than one PIPAC procedures, with an OTR of 76% (38/50) and PCI improvement in 64% (32/50). Ascites volume significantly decreased from 762±1170 ml to 167±456 ml (p=0.02). A high initial Karnofsky Index was correlated with receiving more than one PIPAC (p<0.0001) and a high number of previous surgeries with laparoscopic non-access (p=0.01). Twenty adverse events of Common Terminology Criteria for Adverse Events grade 3 or more were noted. Absence of ascites (odds ratio=8.45, 95% confidence interval=1.9-3.6; p<0.0001), but not patient age, serum cancer antigen-125, and Karnofsky Index independently predicted OTR. EORTC QLQ-30+3 scores for global physical health, nausea/vomiting, appetite loss, and constipation improved during therapy. CONCLUSION:PIPAC with cisplatin and doxorubicin is an active treatment in women with PC and preserves quality of life. Appropriate patient selection regarding performance status and the number of prior surgeries is important. Copyright
Authors: Rafael Seitenfus; Antonio Nocchi Kalil; Eduardo Dipp de Barros; Claudio Galeano Zettler; Gabriel Oliveira Dos Santos; Olivier Glehen; Carlos Humberto Cereser Junior; Paulo Roberto Walter Ferreira Journal: Surg Endosc Date: 2019-08-01 Impact factor: 4.584
Authors: Veria Khosrawipour; Tanja Khosrawipour; Alexander Jens Peter Kern; Aras Osma; Burak Kabakci; David Diaz-Carballo; Eckart Förster; Jürgen Zieren; Khashayar Fakhrian Journal: J Cancer Res Clin Oncol Date: 2016-09-02 Impact factor: 4.553